Assessment of Efficacy and Safety of Magnesium Glycinate in the Management of Selected Inflammatory Diseases
Not Applicable
- Conditions
- Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecifiedHealth Condition 2: J454- Moderate persistent asthmaHealth Condition 3: M179- Osteoarthritis of knee, unspecifiedHealth Condition 4: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
- Registration Number
- CTRI/2024/07/071708
- Lead Sponsor
- M Maneesh Kumar Reddy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with hypomagnesemia (serum magnesium level below 1.6mg/dl)
Age (above 18 years)
Individuals willing to participate in study
Patients on standard therapy managing their inflammatory disorders (Asthma, COPD, Rheumatoid Arthritis and Osteoarthritis)
Both sex
Exclusion Criteria
Known allergy to the any of the drug investigated
Currently using any magnesium related products
Having any psychiatric illness
Administering drugs that affect ADME of investigation product
Presence of alcohol or drug dependence
Evidence of renal or hepatic impairment
Pregnant and lactating women
Participation in any other clinical trials
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method